Supplementary Information for

Construction of a FRET-based ratiometric fluorescent thiol probe

Lingliang Long, Weiying Lin,* Bingbing Chen, Wensha Gao, and Lin Yuan

State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, Hunan 410082, P. R. China

Email: weiyinglin@hnu.cn

Table of contents

		Page
1.	Materials and instruments	
2.	Synthesis	S4-8
3.	Preparation of the test solution	S8
4.	Determination of the fluorescence quantum yield	S8-9
5.	Calculation of energy transfer efficiency	
6.	Cell culture and fluorescence imaging	
7.	Detection of the thiols in biological fluids	S21
8.	Schemes S1-3	S3-S4
9.	Table S1	S11
10.	Figures S1-24	S10-22
11.	References	S23

Materials and instruments: Unless otherwise stated, all reagents were purchased from commercial suppliers and used without further purification. Solvents used were purified by standard methods prior to use. Twice-distilled water was used throughout all experiments. Melting points of compounds were measured on a Beijing Taike XT-4 microscopy melting point apparatus, all melting points were uncorrected; Low resolution mass spectra were performed using an LCQ Advantage ion trap mass spectrometer from Thermo Finnigan or Agilent 1100 HPLC/MSD spectrometer; High resolution mass spectrometric (HRMS) analyses were measured on a Finnigan MAT 95 XP spectrometer. NMR spectra were recorded on an INOVA-400 spectrometer, using TMS as an internal standard; Electronic absorption spectra were obtained on a LabTech UV Power spectrometer; Photoluminescent spectra were recorded with a HITACHI F4600 fluorescence spectrophotometer, with the excitation and emission slit widths at 5.0 nm; Cells imaging were performed with an Olympus FV500 confocal microscope; The pH measurements were carried out on a Mettler-Toledo Delta 320 pH meter; TLC analyses were performed on silica gel plates and column chromatography was conducted over silica gel (mesh 200–300), both of which were obtained from the Qingdao Ocean Chemicals.



Scheme S1. Synthesis of the Bodipy donor building block 2.



Scheme S2. Synthesis of the linker building block 6.



Scheme S3. Synthesis of the reference compound 9.

Synthesis

Synthesis of 4-formylbenzoic succinimidyl ester 1

Compound **1** was synthesized according to the reported procedure (J. A. Phillips, E. L. Morgan, Y. Dong, G. T. Cole, C. McMahan, C.-Y. Hung, S. D. Sanderson, *Bioconjugate Chem.* 2009, **20**, 1950-1957.). ¹H NMR (400 MHz, CDCl₃) δ ppm 10.15 (s, 1H, RC*H*O), 8.32 (d, *J* = 8.4 Hz, 2H, RC₆H₄R'), 8.04 (d, *J* = 8.4 Hz, 2H, RC₆H₄R'), 2.95 (d, *J* = 4.4 Hz, 4H, CH₂); MS (EI): m/z = 247.1 (M)⁺.

Synthesis of Bodipy compound 2

4-formylbenzoic succinimidyl ester **1** (494.4 mg, 2.0 mmol) and 2,4-dimethylpyrrole (380.6 mg, 4.0 mmol) were dissolved in 300 mL dry CH₂Cl₂ (N₂ was bubbled through CH₂Cl₂ for 30 min), and five drops of TFA were added dropwise. The resulting red solution was stirred at room temperature in the dark overnight. After chloranil (495.8 mg, 2.0 mmol) was added, the reaction mixture was stirred for additional four hour, followed by the addition of 3mL Et₃N and 3mL BF₃•OEt₂. After further stirring for 30 min, the reaction mixture was washed three times with water and dried over Na₂SO₄. The solvent was then evaporated and the resulting residue was purified by flash column chromatography (silica gel, CH₂Cl₂: petroleum ether = 1:1, V/V) to give the orange solid **2** (85.0 mg, 9.1%). ¹H NMR (400 MHz, CDCl₃) δ ppm 8.28 (d, *J* = 8.8 Hz, 2H, RC₆H₄R^{*}), 7.50 (d, *J* = 8.4 Hz, 2H, RC₆H₄R^{*}), 6.01 (s, 2H, pyrrole-H), 2.96 (d, *J* = 7.2 Hz, 4H, CH₂), 2.57 (s, 6H, CH₃), 1.38 (s, 6H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ ppm 170.2, 161.3, 155.5, 144.0, 142.5, 141.0, 139.6, 130.8, 129.5, 125.1, 120.6, 30.5, 25.5, 14.2; MS (EI): m/z = 465.2 (M)⁺; C₂₄H₂₂BF₂N₃O₄: calcd. C 61.96, H 4.77, N 9.03; found C 61.67, H 4.91, N 9.31.

Synthesis of 4,4'-dithiodibenzoic acid 3

Compound **3** was synthesized according to the reported procedure (K. Takeda, A. Kuwahara, K. Ohmori, T. Takeuchi, *J. Am. Chem. Soc.* **2009**, *131*, 8833-8838; A. Alagic, A. Koprianiuk, and R. Kluger, *J. Am. Chem. Soc.* **2005**, *127*, 8036-8043.). ¹H NMR (400 MHz, DMSO) δ ppm 7.94 (d, *J* = 8.4 Hz, 4H, RC₆H₄R'), 7.64 (s, *J* = 8.4 Hz, 4H, RC₆H₄R'); MS (ESI): m/z = 305 (M-H)⁻⁻

Synthesis of 4,4'-Dithiodibenzoyl chloride 4

Compound **4** was synthesized according to the reported procedure (A. Alagic, A. Koprianiuk, and R. Kluger, *J. Am. Chem. Soc.* **2005**, *127*, 8036-8043.). ¹H NMR (400 MHz, CDCl₃) δ ppm 8.06 (d, J = 8.8 Hz, 4H, RC₆H₄R²), 7.59 (d, J = 8.8 Hz, 4H, RC₆H₄R²); MS (EI): m/z = 341.9 (M)⁺.

Synthesis of compound 5.

To a solution of 4,4'-Dithiodibenzoyl chloride (2.0 g, 5.9 mmol) and *mono*-Boc-piperazine (2.2 g, 11.7 mmol) in dried CH_2Cl_2 (10 mL) was dropwise added Et_3N (1.5 mL) in dried CH_2Cl_2 (20 mL) over 30 min with stirring at room temperature, and the reaction mixture was further stirred for 30

min. The solvent was evaporated under reduced pressure, and the resulting white solid was recrystallized in ethanol to obtain the pure product (3.5 g) in 92% yield. mp 162-164°C; ¹H NMR (400 MHz, CDCl₃) δ ppm 7.53 (d, J = 8.4 Hz, 4H, RC₆H₄R'), 7.35 (d, J = 8.4 Hz, 4H, RC₆H₄R'), 3.40-3.73 (m, 16H, CH₂), 1.47 (s, 18H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ ppm 169.8, 154.5, 138.7, 134.1, 128.0, 126.8, 80.4, 45.8, 28.3. MS (ESI): m/z = 643.0 (M+H)⁺. C₃₂H₄₂N₄O₆S₂: calcd. C 59.79, H 6.59, N 8.72; found C 59.42, H 6.72, N 8.55.

Synthesis of compound 6

CF₃COOH (1.5 mL) was added to a solution of compound **5** (2.0 g, 3.1 mmol) in CH₂Cl₂ (3 ml), and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated under vacuum, and the resulting residue was dissolved in CH₂Cl₂ (30 mL) and neutralized by 1 M NaOH aqueous solution. The organic phase was separated and dried with MgSO₄. The solvent was then removed under reduced pressure, and the residue was purified by flash column chromatography (silica gel, methanol: CH₂Cl₂ = 1: 1) to give the white solid **6** (0.7 g, 52 %). Mp 54-56°C; ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.42 (s, 2H, -NH-), 7.62 (d, *J* = 8.4 Hz, 4H, RC₆H₄R'), 7.50 (d, *J* = 8.4 Hz, 4H, RC₆H₄R'), 3.60-3.75 (m, 8H, CH₂), 3.11-3.17 (m, 8H, CH₂); ¹³C NMR (100 MHz, DMSO-*d*₆) δ ppm 168.4, 137.5, 133.9, 128.4, 126.5, 42.4. MS (ESI): m/z = 443.1 (M+H)⁺; MS (EI): m/z = 442.1 (M); HRMS (EI): (M)⁺ calcd. for C₂₂H₂₆N₄O₂S₂, 442.1497; found, 442.1503.

Synthesis of Bodipy amide 7

Compound **6** (300.0 mg, 0.7 mmol) and Bodipy succinimidyl ester **2** (200.0 mg, 0.4 mmol) were dissolved in dry CH₂Cl₂ (10 mL), and the reaction mixture was refluxed for 24 hours. The solvent was then evaporated under reduced pressure, and the resulting residue was purified by flash column chromatography (silica gel, CH₂Cl₂: ethanol = 25:1, V/V) to give the orange solid **7** (110.0 mg, 32.3%). Melting point: 150-152°C; ¹H NMR (400 MHz, CDCl₃) δ ppm 7.52-7.58 (m, 6H, ArH), 7.35-7.40 (m, 6H, ArH), 6.00 (s, 2H, pyrrole-H), 2.89-3.78 (m, 16H, CH₂), 2.56 (s, 6H, CH₃), 1.37 (s, 6H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ ppm 169.9, 169.5, 156.0, 142.7, 140.0, 139.3, 138.3, 137.2, 135.6, 134.5, 133.6, 131.1, 128.6, 128.1, 126.9, 121.5, 62.1, 29.7, 14.6; MS (ESI): m/z = 793.1 (M+H)⁺. C₄₂H₄₃BF₂N₆O₃S₂: calcd. C 63.63, H 5.47, N 10.60; found C 63.38, H

5.77, N 10.75.

Synthesis of compound 8

NaBH₄ (12.5 mg, 0.3 mmol) was added to a solution of compound 7 (26.0 mg, 0.03 mmol) in THF (8 mL), and the reaction was stirred at room temperature for 10 min (The reduction reaction was essentially complete within 10 min by the TLC analysis). The reaction was then quenched by addition of saturated NH₄Cl aqueous solution (40 mL), and the solution was extracted with $CH_2Cl_2(3 \times 40 \text{ mL})$. The organic layer was combined, washed with water (50 mL), and dried with MgSO₄. The solvent was evaporated under reduced pressure, and the resulting residue was purified by flash column chromatography (silica gel, CH_2Cl_2 : ethanol = 100:1, V/V) to give orange solid **8** (14.2 mg, 75%). Mp160-163°C; ¹H NMR (400 MHz, CDCl₃) δ ppm 7.54-7.58 (m, 4H, ArH), 7.39 (d, *J* = 6.8 Hz, 4H, ArH), 6.00 (s, 2H, pyrrole-H), 3.53-3.74 (m, 8H, CH₂), 2.56 (s, 6H, CH₃), 1.38 (s, 6H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ ppm 169.1, 158.3, 155.6, 143.1, 142.3, 142.0, 141.8, 137.3, 134.5, 130.8, 130.5, 128.8, 128.3, 127.0, 121.9, 63.5, 31.2, 14.5; MS (ESI): m/z = 571.2 (M-H)⁻. C₃₁H₃₁BF₂N₄O₂S: calcd. C 65.04, H 5.46, N 9.79; found C 64.69, H 5.70, N 9.88.

Synthesis of probe NRFTP

A solution of rhodamine B (150.0 mg, 0.3 mmol) and phosphorus oxychloride (1 mL) in 1,2-dichloromethane (20 mL) was refluxed for 4 h. After cooling, the reaction mixture was concentrated under reduced pressure to obtain crude rhodamine acid chloride, which was then added to a solution of compound **8** (149.0 mg, 0.26 mmol) in dry CH₂Cl₂ (5 mL). After the reaction mixture was stirred for 1 min, Et₃N (0.3 mL) was then added, and the reaction mixture was further stirred at room temperature for 2h. The solvent was evaporated under reduced pressure, and the resulting residue was purified by flash column chromatography (silica gel, CH₂Cl₂: ethanol : petroleum ether = 15:1:5, V/V) to give the compound **NRFTP** as a purple solid (76.0 mg, 29.5%). ¹H NMR (400 MHz, CDCl₃) δ ppm 8.35 (d, *J* = 7.6 Hz, 1H, ArH), 7.83-7.88 (m, 2H, ArH), 7.55 (d, *J* = 8.0 Hz, 2H, ArH), 7.38-7.40 (m, 5H, ArH), 7.32 (d, *J* = 7.6 Hz, 2H, ArH), 7.12 (d, *J* = 9.2 Hz, 2H, ArH), 6.89 (dd, *J* = 9.6, 2 Hz, 2H, ArH), 6.81 (d, *J* = 2.4 Hz, 2H, ArH), 5.99 (s, 2H, pyrrole-H), 3.60-3.65 (m, 16H, CH₂), 2.56 (s, 6H, CH₃), 1.36 (s, 6H, CH₃), 1.31 (t, *J* = 7.2 Hz,

12H, CH₃); ¹³C NMR (100 MHz, CDCl₃) δ ppm 173.3, 172.9, 167.8, 157.8, 155.75, 155.71, 139.1, 137.1, 136.8, 132.5, 131.2, 131.0, 130.9, 130.1, 129.8, 128.9, 128.8, 128.5, 128.3, 127.1, 126.8, 121.5, 121.4, 114.0, 96.3, 62.1, 46.2, 32.0, 14.2, 12.7; MS (ESI): m/z = 997 (M)⁺; HRMS (FAB): (M)⁺ calcd. for C₅₉H₆₀BF₂N₆O₄S⁺ 997.4452; found, 997.4456.

Synthesis of the reference compound 9

Compound **9** was prepared by employing the same procedure for the synthesis of compound **NRFTP** except that 4-bromobenzenethiol (228.0 mg, 1.1 mmol) in dry CH_2Cl_2 (10 mL) was used. The residue was purified by flash column chromatography (silica gel, acetone) to give compound **9** as a purple solid (385.0 mg, 53%). ¹H NMR (400 MHz, CDCl₃) δ ppm 8.35 (dd, J = 7.6, 0.8 Hz, 1 H, ArH), 7.90 (t, J = 7.2, 1H, ArH), 7.83 (t, J = 8.0 Hz, 1H, ArH), 7.45 (d, J = 8.8 Hz, 2H, ArH), 7.39 (d, J = 7.2 Hz, 1H, ArH), 7.11 (d, J = 9.2Hz, 4H, ArH), 6.93 (dd, J = 7.2, 2.4 Hz, 2H, ArH), 6.77 (d, J = 2.4Hz, 2H, ArH), 3.64 (q, J = 7.2Hz, 8H, CH₂), 1.32 (t, J = 7.2Hz, 12H, CH₃). MS (ESI): m/z = 613.2 (M)⁺. HRMS (EI): (M)⁺ calcd. for C₃₄H₃₄BrN₂O₂S, 613.1519; found, 613.1515.

Preparation of the test solution.

A stock solution of probe **NRFTP** (1.3×10^{-3} M) was prepared in CH₃CN. The test solution of the probe (1.3μ M) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent) was prepared by placing 0.002 mL of the probe stock solution, 0.9 mL CH₃CN, and 1.1 mL of 45.5 mM sodium phosphate buffer (pH = 7.4). The solutions of various testing species were prepared from Cys, Phe, Ala, Gly, Glu, Arg, Lys, Tys, Leu, Ser, Val, glucose, KCl, CaCl₂, ZnCl₂, FeCl₃, H₂O₂, NADH, respectively. The resulting solution was shaken well and incubated for 20 min at room temperature before recording the spectra.

Determination of fluorescence quantum yield: ¹⁻⁴

Fluorescence quantum yield was determined using optically matching solutions of rhodamine $6G (\Phi_{F(S)} = 0.9 \text{ in ethanol}^5)$ or fluorescein ($\Phi_{F(S)} = 0.93$ in H₂O⁶) as a standard. The quantum yield was calculated using the following equation:

$$\Phi_{\mathrm{F}(\mathrm{X})} = \Phi_{\mathrm{F}(\mathrm{S})} \left(A_{S} F_{X} / A_{X} F_{S} \right) \left(n_{X} / n_{S} \right)^{2}$$

Where Φ_F is the fluorescence quantum yield, *A* is the absorbance at the excitation wavelength, *F* is the area under the corrected emission curve, and *n* is the refractive index of the solvents used. Subscripts s and x refer to the standard and to the unknown, respectively.

Calculation of energy transfer efficiency 7-10

Energy transfer efficiency (E) was calculated using the following equation as reported. ⁷⁻¹⁰

$$E = 1 - F_{DA} / F_D$$

Where, F_{DA} and F_{D} denote the donor fluorescence intensity with and without an acceptor, respectively.

Cell culture and fluorescence imaging.

Hela cells were seeded in a 6-well plate in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum for 24 h. Hela cells were then incubated with probe **NRFTP** (2 μ M) in the culture medium for 30 min at 37°C. After washing with PBS three times to remove the remaining probe, the confocal fluorescence images were acquired with an OLYMPUS FV500 confocal microscope. Excitation wavelength of laser was 488 nm, and emissions were centered at 515 ± 10 nm and 610 ± 10 nm (double channels). For the N-ethylmaleimide control experiment, the cell were pretreated with N-ethylmaleimide (1 mM) for 30 min at 37°C followed by washing with PBS three times, and then incubated with probe **NRFTP** (2 μ M) for 30 min at 37°C. Fluorescence imaging was then carried out after washing the cells with PBS buffer three times.



Figure S1. NCL mechanism-based design of ratiometric fluorescent thiol probe NRFTP.



Figure S2. Energy minimized (HyperChem v. 7.5, PM3 semi-empirical module) structure of probe NRFTP. Calculated B-O distance 22.88 Å.



Figure S3. The absorption spectra of probe NRFTP (1.3 μ M) (**•**), reference Bodipy donor **8** (1.3 μ M) (**•**), and reference rhodamine acceptor **9** (1.3 μ M) (**•**) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent).

compound	$\lambda_{ m abs}$ (nm)	Logε (M⁻¹cm⁻¹)	$\lambda_{ m em}$ (nm)	${\pmb \Phi}_{f}$
NRFTP	500	4.73	510	0.005 ^[a]
	562	4.91	590	0.162 ^[a]
8	498	4.69	511	0.464 ^[a]
9	562	4.90	590	0.186 ^[b]
10				0.003 ^[b]

Table S1. The spectroscopic data for compounds NRFTP and 8-10.

[a] λ_{ex} = 470 nm. [b] λ_{ex} = 540 nm



Figure S4. The fluorescence emission spectra of the probe NRFTP (1.3 μ M) (•), the reference Bodipy donor 8 (1.3 μ M) (•), and the reference rhodamine acceptor 9 (1.3 μ M) (\bigstar) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent). The excitation wavelength was 470 nm.



Figure S5. The absorption (\blacktriangle) and corrected excitation (\blacksquare) spectra of probe NRFTP in phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent). The excitation spectrum was monitored at 590 nm.



Figure S6. Absorption spectral changes of probe NRFTP (1.3 μ M) upon addition of Cys (0 – 100 μ M) in phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent). The spectral were recorded after mixing Cys with probe NRFTP for 20 minutes.



Figure S7. Plot of the fluorescence intensity ratios at 510 and 590 nm (I_{510}/I_{590}) as a function of the Cys concentration.



Figure S8. Fluorescence spectra (with excitation at 470 nm) of probe **NRFTP** (1.3 μ M) upon addition of increasing concentrations (0 - 200 μ M) of homocysteine (a) or glutathione (b) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent).



Figure S9. Fluorescence spectral changes (with excitation at 550 nm) of probe NRFTP (1.3 μ M) upon addition of increasing concentrations (0 - 200 μ M) of Cys. The inset shows the changes of fluorescent intensity at 590 nm (λ_{ex} = 550 nm) to increasing concentration of Cys.



Figure S10. The absorption spectra of the reference rhodamine acceptor **9** (1.3 μ M) in the absence (**•**) or presence (**•**) of Cys (100 μ M) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent).



Figure S11. The fluorescence emission spectra ($\lambda_{ex} = 550$ nm) of the reference rhodamine acceptor **9** (1.3 μ M) in the absence (•) or presence (•) of Cys (100 μ M) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent).



Figure S12. Partial ¹H NMR (400 MHz) spectra of (a) the separated product **8** of probe NRFTP + Cys, and (b) the standard compound **8**.



Figure S13. Partial Mass spectra of (a) the separated product 8 of probe NRFTP + Cys, and (b) the standard compound 8.



Figure S14. ¹H NMR (400 MHz) spectrum of the isolated product **10** of probe NRFTP + Cys.



Figure S15. Mass spectrum of the isolated product 10 of probe NRFTP + Cys.



Figure S16. The fluorescence spectra (with excitation at 470 nm) of NRFTP (1.3 μ M) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent) kept for 0.5 hour (\blacktriangle) and for 3 day (\bigstar). For comparison, the fluorescence spectrum of NRFTP ($\lambda_{ex} = 470$ nm) with addition of Cys (100 μ M) for 20 min was also showed (\blacksquare).



Figure S17. Fluorescence intensity at 590 nm for the probe NRFTP in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH_3CN as a co-solvent) after excitation at 470 nm for 0-30 minutes.



Figure S18. Time dependent fluorescence ratio changes of probe NRFTP (1.3 μ M) in the absence (**•**) or presence of 100 μ M Cys (\bigstar).



Figure S19. The fluorescence intensity ratios at 510 and 590 nm (I_{510}/I_{590}) for probe **NRFTP** (1.3 μ M) in the absence (\blacksquare) or presence (\bigcirc) of Cys (100 μ M) at various pH values. The excitation wavelength was 470 nm.



Figure S20. Ratiometric fluorescence (I_{510} / I_{590}) response of probe NRFTP (1.3 µM) to 100 µM of Cys in the presence of 100 µM of various species: (1) Free; (2) KCl; (3) CaCl₂; (4) ZnCl₂; (5) FeCl₃; (6) glucose; (7) NaDH; (8) H₂O₂; (9) Phe; (10) Ala; (11) Gly; (12) Glu; (13) Arg; (14) Lys; (15) Tys; (16) Leu; (17) Ser; (18) Val. $\lambda_{ex} = 470$ nm.



Figure S21. Color changes of probe NRFTP (1.3 μ M) in the presence of 100 μ M various species. 1: free, 2: Phe, 3: Ala, 4: Tys, 5: Cys, 6: Ser, 7: glucose. (a) visible color and (b) visual fluorescence color on excitation at 365 nm using a handheld UV lamp.

Detection of the thiols in biological fluids.

For the thiol assay in newborn-calf serum, the serum typically requires the reduction of disulfides to free thiols. This can be accomplished by using an excess of triphenylphosphine at room temperature¹¹⁻¹³. 2 mL newborn-calf serum sample was firstly diluted with 1 mL distilled water, then treated with 1 mL triphenylphosphine solution in CH₃CN (1.5 $\times 10^{-3}$ M) for 30 min, after filtration, the reduced serum was directly used for the thiol assay. For the thiol assay in human urine, the sample was taken from a healthy volunteer. 1 mL urine sample was treated with 1 mL triphenylphosphine solution in CH₃CN (1.5 $\times 10^{-3}$ M) for 30 min, after filtration, the reduced sample was directly used for the thiol assay. Aliquots of the reduced newborn-calf serum solution or the reduced human urine samples were then added directly to a solution of probe **NRFTP** (1.3 μ M, the total volume was 2 mL) in 25 mM potassium phosphate buffer (pH 7.4, containing 45% CH₃CN as a co-solvent). Then the fluorescent intensity ratio at 510 and 590 nm (I_{510}/I_{590}) ($\lambda_{ex} = 470$ nm) was recorded. The unknown amount of thiols in the human urine sample was estimated by using the standard addition method with Cys as the standard.^{12, 14} The total content of thiols in the urine sample was analyzed to be $40 \pm 3 \mu M$, which is well within the reported thiol concentration range for the urine samples from the healthy individuals ((a) T. Inoue, J. R. Kirchhoff, Anal. Chem. 2002, 74, 1349; (b) M. P. Brigham, W. H. Stein, S. Moore, J. Clin. *Invest.* 1960, **39**, 1633.). The result is in good agreement with the value $(36 \pm 4 \mu M)$ obtained for our sample by employing a fluorescent thiol probe reported by Peng et al. (*Chem Commun.*, 2009, 5904-5906.).



Figure S22. Linear relationship between the emission ratios and the volume of reduced newborn-calf serum added. The data were obtained by addition of different amounts of reduced new born-calf serum sample (0, 50, 100, 200, 300, 400 or 500 μ L) to probe **NRFTP** (1.3 μ M). Excitation at 470 nm.



Figure S23. Cytotoxicity of **NRFTP** in cultured Hela cells. The cells were incubated with the probe at different concentrations for 24 h. The cell viability was measured by the MTT assay, and the data are reported as the percentage relative to the untreated cells.



Figure 24. (a) Ratio fluorescence (I_{515} / I_{610}) image of Hela cells incubated with probe NRFTP (2 μ M). (b) Ratio fluorescence (I_{515} / I_{610}) image of Hela cells pretreated with the thiol-blocking reagent *N*-ethylmaleimide (1 mM), then incubated with probe NRFTP (2 μ M). The ratio imaging data were obtained using commercial software (Fluoview version 4.3).

References:

- 1 C. A. Parker, W. T. Rees, *Analyst* 1960, **85**, 587.
- 2 S. F. Forgues, D. Lavabre, J. Chem. Educ. 1999, 76, 1260.
- 3 A. Ajayaghosh, P. Carol, S. Sreejith, J. Am. Chem. Soc. 2005, 127, 14962.
- 4 W. Lin, L. Yuan, W. Tan, J. Feng, L. Long, *Chem. Eur. J.* 2009, **15**, 1030.
- 5 V. K. Praveen, S. J. George, R. Varghese, C. Vijayakumar, A. Ajayaghosh, *J. Am. Chem. Soc.* 2006, **128**, 7542.
- 6 G. Weber, F. W. J. Teale, *Trans. Faraday Soc.* 1958, **54**, 640.
- 7 J. R. Lakowicz, *Topics in Fluorescence Spectroscopy, Volume 2: Principles*; Kluwer Academic Publishers: New York, 2002, pp.130-132.
- 8 D. Seth, A. Chakraborty, P. Setua, D. Chakrabarty, N. Sarkar, J. Phys. Chem. B. 2005, 109, 12080.
- 9 S. L. Gilat, A. Adronov, J. M. J. Fréchet, Angew. Chem., Int. Ed. 1999, 38, 1422.
- 10 M. H. Lee, D. T. Quang, H. S. Jung, J. Yoon, C. H. Lee, J. S. Kim, *J. Org. Chem.* 2007, **72**, 4242.
- 11 W. Wang, J.O. Escobedo, C.M. Lawrence, R. M. Strongin, *J. Am. Chem. Soc.* 2004, **126**, 3400.
- 12 H. Shiu, H. Chong, Y. Leung, M. Wong, C. Che, Chem. Eur. J. 2010, 16, 3308.
- 13 A. R. Ivanov, I. V. Nazimov, L. A. Baratova, J. Chromatogr. A 2000, 895, 167.
- 14 S. Sreejith, K. P. Divya, A. Ajayaghosh, Angew. Chem. Int. Ed. 2008, 47, 7883.

